Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
Active, not recruiting · Phase 1 · NCT05353439
Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Biopsy Procedure (procedure), Biospecimen Collection (procedure), Computed Tomography (procedure), Pembrolizumab (biological), Tazemetostat Hydrobromide (drug), Topotecan Hydrochloride (drug)
- Dates
- Started 2022-07-27; completion 2027-03-13
- Results posted
- Not yet
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tum…
From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $1.0M in research payments for this study in 2025 (2 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anish J. Thomas, M.D Interventional Cardiology · Saint Louis, MO
- Anish Thomas, MD Student in an Organized Health Care Education/Training Program · Syracuse, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Cancer Institute Frederick Campus $1.0M
- Nci Cancer Therapy Evaluation Program $3,850
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.